Biotech Spyre Therapeutics launches public offering of its common stock
Proceeds would advance its gastroenterology, rheumatology and dermatology programs, including SPY072 for hidradenitis suppurativa.
Spyre Therapeutics Issuer
Intelligence
The deal
- Type
- Funding
- Amount
- Not recorded
- Status
- Announced
- Round
- Public offering
- Valuation
- Not recorded
- Region
- United States
- Date
- 5 October 2026
As of this development: a later development may record new terms.
Lifecycle
- Announced
- Closed
The parties
Spyre Therapeutics Issuer
Activity